Sosei Group Stock Price, News & Analysis (OTCMKTS:SOLTF) $9.48 -0.47 (-4.72%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$9.48▼$9.7150-Day Range$8.93▼$10.4152-Week Range$8.93▼$22.78Volume1,100 shsAverage Volume1,582 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest About Sosei Group Stock (OTCMKTS:SOLTF)Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.Read More SOLTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SOLTF Stock News HeadlinesNovember 24, 2023 | finance.yahoo.comSosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel DiseaseNovember 14, 2023 | morningstar.comSosei Group Corp 4565December 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 10, 2023 | msn.comSosei Group reports Q3 resultsNovember 10, 2023 | finance.yahoo.comSosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal DiseasesNovember 10, 2023 | finance.yahoo.comSosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023November 7, 2023 | finance.yahoo.comSosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2023November 5, 2023 | finance.yahoo.comSosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 TrialDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 31, 2023 | finance.yahoo.comSosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of InsomniaOctober 31, 2023 | finance.yahoo.comSosei Heptares Will Receive US$3.75 Million Payment in Multi-Target PartnershipOctober 25, 2023 | finance.yahoo.comSosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development ProgressOctober 18, 2023 | finance.yahoo.comSosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023October 10, 2023 | msn.comSosei and PharmEnable collaborate on another neurological drugOctober 4, 2023 | finance.yahoo.comSosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic DevelopmentSeptember 20, 2023 | finance.yahoo.comSosei Heptares Adds World-leading Expertise to its Scientific Advisory BoardAugust 10, 2023 | finance.yahoo.comSosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732August 4, 2023 | finance.yahoo.comSosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023July 21, 2023 | reuters.comSosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 million - NikkeiJune 27, 2023 | marketwatch.comSosei Group Shares Indicated Lower After Partner Pfizer Terminates Diabetes Drug DevelopmentJune 3, 2023 | msn.comSosei Group (TYO:4565) Price Target Increased by 5.50% to 3,351.43April 5, 2023 | finance.yahoo.comSosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ MeetingMarch 18, 2023 | finance.yahoo.comSosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime MarketDecember 22, 2022 | reuters.comSosei Group CorpNovember 8, 2022 | finance.yahoo.comPrecisionLife to Evaluate Precision Medicine Potential of Sosei Heptares Neuroscience GPCR TargetSeptember 17, 2022 | investing.comSosei Group Corp (4565)September 13, 2022 | msn.comEXCLUSIVE | Ola Electric rejigs roles to unify operations across roles; YS Kim gets larger roleSee More Headlines Receive SOLTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sosei Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SOLTF CUSIPN/A CIKN/A Webwww.sosei.com Phone(135) 210-3290FaxN/AEmployees348Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Shinichi Tamura (Age 74)Founder & Chairman of the Board Comp: $1.54MMr. Christopher Cargill (Age 39)Representative Executive Officer, President, CEO & Director Comp: $1.32MMr. Hironoshin Nomura (Age 40)Executive Officer, Executive VP & CFO Mr. Kieran Johnson F.C.A. (Age 54)Executive Officer, Executive VP & Chief Accounting Officer Dr. Miles CongreveChief Scientific OfficerMr. Kazuhiko Yoshizumi (Age 69)Executive Officer, Executive VP & Chief Compliance Officer Shinichiro NishishitaVP of Investor Relations & Head of Regulatory DisclosuresStacey SouthallAssociate Director & Head of BiophysicsMs. Candelle Chong (Age 34)Executive Officer, Executive VP & Chief of Staff Dr. Satoshi TanakaExecutive Officer, Executive VP & President of Idorsia Pharmaceuticals JapanMore ExecutivesKey Competitors3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAgentixOTCMKTS:AGTXView All Competitors SOLTF Stock Analysis - Frequently Asked Questions Should I buy or sell Sosei Group stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sosei Group in the last twelve months. There are currently 2 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "sell" SOLTF shares. View SOLTF analyst ratings or view top-rated stocks. How have SOLTF shares performed in 2023? Sosei Group's stock was trading at $15.5439 at the start of the year. Since then, SOLTF shares have decreased by 39.0% and is now trading at $9.48. View the best growth stocks for 2023 here. Are investors shorting Sosei Group? Sosei Group saw a decline in short interest in November. As of November 15th, there was short interest totaling 1,062,100 shares, a decline of 29.0% from the October 31st total of 1,495,200 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is currently 5,310.5 days. View Sosei Group's Short Interest. How do I buy shares of Sosei Group? Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:SOLTF) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sosei Group Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.